MMP-2 positivity and age less than 40 years increases the risk for recurrence in premenopausal patients with node-positive breast carcinoma

Breast Cancer Research and Treatment

Volumn 58, Issue 3, 1999, Pages 287-293

  Talvensaari Mattila, Anne ^a,b   Pääkkö, Paavo ^b   Turpeenniemi Hujanen, Taina ^a  

^a OULU UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF OULU   (Finland)

Author keywords

72 kDa type IV collagenase; Breast cancer; Gelatinase A; Hematogenous metastasis; Prognostic factors

Indexed keywords

GELATINASE A; MONOCLONAL ANTIBODY; PARAFFIN;

ADJUVANT CHEMOTHERAPY; ADULT; AGE; ARTICLE; BREAST CARCINOMA; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; DEVICE; FEMALE; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PREDICTION; PREMENOPAUSE; PRIORITY JOURNAL; PROGNOSIS; TISSUE SECTION; TUMOR;

EID: 0033490751     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/a:1006326513176     Document Type: Article

References (41)

1. 1. Cody HS: The impact of mammography in 1096 consecutive patients with breast cancer, 1979-1993. Equal value for patients younger and older than 50 years. Cancer 76: 1579-1584, 1995
2. 2. Valero V, Buzdar A, Hortobagyi G: Locally advanced breast cancer. Oncologist J: 8-17, 1996
3. 3. Mouridsen HT, Rose C, Brincker H: Adjuvant systemic therapy in high-risk breast cancer. The Danish Breast Cancer Cooperative Group's trials of cyclophosphamide or CMF in premenopausal and tamoxifen in postmenopausal patients. In: Senn HJ, (ed) Recent Results in Cancer Research, Adjuvant Chemotherapy of Breast Cancer. Heidelberg, Springer, 1984
4. 4. Stetler-Stevenson WO, Liotta LA, Kleiner DE Jr: Extracellular matrix; Role of matrix metalloproteinase in tumour invasion and metastasis. FASEB J 7: 1434-1441, 1993
5. 5. Höyhtyä M, Fridman R, Komareck D, Porter-Jordan K, StetlerStevenson WG, Liotta LA, Liang C-M: Immunohistochemical localization of matrix metailoproteinase 2 and its specific inhibitor TIMP-2 in neoplastic tissue with monoclonal antibodies. Int J Cancer 54: 500-505, 1994
6. 6. Tryggvason K, Höyhtyä M, Pyke C: Type IV collagenases in invasive tumours. Breast Cancer Res Treat 24: 209-218, 1993
7. 7. Monteagudo C, Merino MJ, San-Juan J, Liotta LA, Stetler-Stevenson WG: Immunohistochemical distribution of type IV collagenase in normal, benign, and malignant breast tissue. Am J Pathol 136: 585-592, 1990
8. 8. Davies B, Miles DW, Happerfield LC, Naylor MS, Bobrow LG, Rubens RD, Balkwill FR: Activity of type IV collagenases in benign and malignant breast disease. Br J Cancer 67: 1126-1131, 1993
9. 9. Visscher DW, Höyhtyä M, Ottosen SK, Liang C-M, Sarka FH, Crissman JD: Enhanced expression of tissue inhibitor of metalloproteinase-2 ( TIMP-2 ) in stroma of breast carcinomas correlates with tumour recurrence. Int J Cancer 59: 339-344, 1994
10. 10. Daidone MG, Silvestrini R, D'Errico A, Di Fronzo C, Benini E, Mancini AM, Garbisa S, Liotta LA, Grigioni WF: Laminin receptors, collagenase IV and prognosis in node-negative breast cancers. Int J Cancer 48: 529-532, 1991
11. 11. Talvensaari-Mattila A, Pääkkö P, Höyhtyä M, Blanco-Sequeiros G, Turpeenniemi-Hujanen T: Matrix metalloproteinase-2 immunoreactive protein, a marker of aggressiveness in breast carcinoma. Cancer 83: 1153-1162, 1998
12. 12. Hermanek P, Sobin LH, eds: UICC TNM Classification of malignant tumours. 4th ed. 2nd rev. Berlin: Springer-Verlag, 1992
13. 13. Scarff RW, Torloni H: Histological typing of breast tumours. WHO: Geneva, 1986
14. 14. Bloom HJG, Richardson WW: Histological grading and prognosis in breast cancer. Br J Cancer 11: 359-377, 1957
15. 15. Hsu SM, Raine L, Fanger H: The use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase technique: A comparison between ABC and unlabeled antiboby (PAP) procedures. J Histochem Cytochem 29: 577-580, 1981
16. 16. Marqulies IMK, Höyhtyä M, Evans C, Stracke ML, Liotta LA, Stetler-Stevenson WG: Urinary type IV collagenase elevated levels are associated with bladder transitional cell carcinoma. Cancer Epidemiol Biomarkers & Prevention 467-474, 1992
17. 17. Autio-Harmainen H, Hurskainen T, Niskasaari K, Höyhtyä M, Tryggvason K: Simultaneous expression of 72 kilodalton type IV collagenase and type IV collagen α1(IV) chain genes by cells of early human placenta and gestational endometrium. Lab Invest 67: 191-200, 1992
18. 18. Autlo-Harmainen H, Karttunen T, Hurskainen T, Höyhtyä M, Kauppila A, Tryggvason K: Expression of 72 kDa type IV collagenase in benign and malignant ovarian tumors. Lab Invest 69: 312-321, 1993
19. 19. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481, 1958
20. 20. Mantel N: Evaluation of survival data and two new rank order statistics arising in this consideration. Cancer Chemother Rep 50: 163-170, 1966
21. 21. Nixon AJ, Neuberg D, Hayes DF, Gelman R, Connolly JL, Schitt S, Abner A, Recht A, Vicini F, Harris JR: Relationship of patient age to pathologic features of the tumor and prognosis for patients with stage I or II breast cancer. J Clin Oncol 12: 888-894, 1994
22. 22. Rochefordiere A, Asselain B, Campana F, Scholl S, Fenton J, Vilcoq JR, Durand J-C, Pouillart P, Magdelenat H, Fourquet A: Age as prognostic factor in premenopausal breast carcinoma. Lancet 341: 1039-1043, 1993
23. 23. Boyages J, Recht A, Connolly JL, Schnitt SJ, Gelman R, Kooy H, Love S, Osteen RT, Cady B, Silver B, Harris JR: Early breast cancer: predictors of breast recurrence for patients treated with conservative surgery and radiation therapy. Radiotherapy Oncol 19: 29-41, 1990
24. 24. Solin LJ, Fowble B, Schultz DJ, Goodman RL: Age as a prognostic factor for patients treated with definitive irradiation for early stage breast cancer. Int J Radiat Oncol Biol Phys 16: 373-381, 1989
25. 25. Bartelink H, Borger JH, van Dongen JA, Peterse JL: The impact of tumor size and histology on local control after breast-conserving therapy. Radiotherapy Oncol 11: 297-303, 1988
26. 26. Crowe JP, Gordon NH, Shenk RR, Zollinger RM, Brumberg DJ, Shuck JM: Age does not predict breast cancer outcome. Arch Surg 129: 483-488, 1994
27. 27. Kini VR, White JR, Horwitz EM, Dmuchowski CF, Marlinez AA, Vicini FA: Long term results with breast-conserving therapy for patients with early stage breast carcinoma in a community hospital setting. Cancer 82: 127-133, 1988
28. 28. Kim SH, Simkovich- Heerdt A, Tran KN, Maclean B, Borgen PI: Women 35 years of age or younger have higher locoregional relapse rates after undergoing breast conservation therapy. J Am Coll Surg 187: 1-8, 1998
29. 29. Väisänen A, Kallioinen M, Taskinen P, Turpeenniemi-Hujanen T: Prognostic value of MMP-2 immunoreactive protein (72 kD type IV collagenase) in primary skin melanoma. J Pathol 186: 51-58, 1998
30. 30. Väisänen A, Tuominen H, Kallioinen M, Turpeenniemi-Hujanen T: Matrix metalloproteinase-2 (72 kD type IV collagenase) expression occurs in the early stage of human melanocytic tumour progression and may have prognostic value. J Pathol 180: 283-289, 1996
31. 31. Väisänen A, Kallioinen M, von Dickhoff K, Laatikainen L, Höyhtyä M, Turpeenniemi-Hujanen T: Matrix metalloproteinase-2 (MMP-2) immunoreactive protein - a new prognostic marker in uveal melanoma? J Pathol 188: 56-62, 1999
32. 32. Foidart JM: Stromal proteases in the progression of breast cancer. Bulletin et Memoires de I Academie Royale de Medecine de Belgique 152: 229-235, 1997
33. 33. Polette M, Gilbert N, Stas I, Nawrocki B, Noel A, Remace A, Stetler-Stevenson WG, Birembaut P, Foidart M: Gelatinase A expression and localization in human breast cancers. An in situ hybridization study and immunohistochemical detection using confocal microscopy. Virchows Archiv 424: 641-645, 1994
34. 34. Clavel C, Polette M, Doco M, Binninger I, Birembaut P: Immunolocalization of matrix metallo-proteinases and their tissue inhibitor in human mammary pathology. Bull Cancer 79: 261-270, 1992
35. 35. Levy AT, Cioce V, Sobel ME, Garbisa S, Grigioni WF, Liotta LA, Stetler-Stevenson W: Increased expression of the Mr 70,000 type IV collagenase in human colonic adenocarcinoma. Cancer Res 51: 439-444, 1991
36. 36. Pyke C, Ralfkiaer E, Tryggvason K, Dano K: Messenger RNA for two type IV collagenases is located in nonmalignant stromal cells in human colon cancer. Am J Pathol 142: 359-365, 1993
37. 37. Poulsom R, Pignatelli M, Stetler-Stevenson WG, Liotta LA, Wright PA, Jeffery RE, Longcroft JM, Rogers L, Stamp GW: Stromal expression of 72 kda type IV collagenase (MMP-2) and TIMP-2 mRNAs in colorectal neoplasia. Am J Pathol 141 : 389-396, 1992
38. 38. Poulsom R, Hanby AM, Pignatelli M, Jeffery RE, Longcroft JM, Rogers L, Stamp GW: Expression of gelatinase A and TIMP-2 mRNAs in desmoplastic fibroblasts in both mammary carcinomas and basal cell carcinomas of the skin. J Clin Pathol 46: 429-436, 1993
39. 39. Okada A, Bellocq JP, Rouyer N, Chenard MP, Rio MC, Chambon P, Basset P: Membrane-type matrix metalloproteinase (MT-MMP) gene is expressed in stromal cells of human colon, breast, and head and neck carcinomas. Proc Natl Acad Sci 92: 2730-2734, 1995
40. 40. Wolf C, Rouyer N, Lutz Y, Adida C, Loriot M, Bellocq JP, Chambon P, Basset P: Stromelysin 3 belongs to a subgroup of proteinases expressed in breast carcinoma fibroblastic cells and possibly implicated in tumor progression. Proc Natl Acad Sci 90: 1843-1847, 1993
41. 41. Ueno H, Nakamura H, Inoue M, Imai K, Noguchi M, Sato H, Seiki M, Okada Y: Expression and tissue localization of membrane-types 1, 2, and 3 matrix metalloproteinases in human invasive breast carcinomas. Cancer Res 57: 2055-2060, 1997